What do low‑attenuation lesions in the proximal pancreatic tail measuring 2.9 × 1.3 cm with associated atrophy of the distal pancreatic tail and dilatation of the pancreatic duct, together with a 1.7 cm low‑attenuation lesion in the right hepatic lobe on contrast‑enhanced abdominal CT indicate, and what is the likely prognosis?

Highly Suspicious for Pancreatic Ductal Adenocarcinoma with Possible Hepatic Metastasis

This imaging pattern—a 2.9 cm low-attenuation pancreatic tail lesion with distal pancreatic atrophy and pancreatic duct dilatation, combined with a 1.7 cm hepatic lesion—is highly concerning for pancreatic ductal adenocarcinoma (PDAC) with potential liver metastasis, and requires urgent further evaluation with EUS-FNA and consideration of surgical consultation if no metastatic disease is confirmed.

What These Findings Indicate

Pancreatic Findings: Classic Signs of Malignancy

The constellation of findings in the pancreas represents high-risk features strongly associated with PDAC [1, 2:

• Low-attenuation focal lesion (2.9 × 1.3 cm): Pancreatic adenocarcinomas typically appear as hypoattenuating (low-attenuation) masses on contrast-enhanced CT, particularly during the pancreatic phase [3, 4

• Distal pancreatic atrophy: This is a critical secondary sign of pancreatic malignancy. Focal pancreatic parenchymal atrophy (FPPA) occurs in approximately 28% of PDAC patients and can appear up to 35 months before diagnosis 5. When present with a mass, it strongly suggests malignant obstruction of the pancreatic duct 6

• Pancreatic duct ectasia (dilatation): Main pancreatic duct dilation is both a worrisome feature and potential high-risk stigmata depending on degree. Duct dilation ≥5-9 mm warrants EUS-FNA, while ≥10 mm may indicate need for surgical evaluation [1, 1. The combination of duct cutoff with dilatation and distal atrophy has 97% agreement as an indication for resection in high-risk surveillance 7

This triad—mass, duct dilation, and distal atrophy—is pathognomonic for pancreatic malignancy [2, [8, 6. Research shows that abrupt pancreatic duct cutoff with distal atrophy, parenchymal contour abnormality, and associated mass have odds ratios of 7.6-13.7 for malignancy 8.

Hepatic Finding: Concerning for Metastasis

The 1.7 cm low-attenuation lesion in the right hepatic lobe raises significant concern for metastatic disease:

• Liver is the most common site of pancreatic cancer metastasis 9
• Low-attenuation hepatic lesions in the context of known or suspected pancreatic malignancy should be presumed metastatic until proven otherwise
• MRI is more sensitive than CT for detecting small liver metastases, identifying occult lesions in 10-23% of cases that appear resectable on CT alone 10

Immediate Next Steps

1. Obtain High-Quality Pancreatic Protocol CT (if not already done)

The initial CT should be reviewed to confirm it was performed with proper pancreatic protocol [3, 11:

• Thin-section (submillimeter) multidetector CT
• Dual-phase imaging (pancreatic and portal venous phases)
• IV contrast at 1.5 ml/kg at 4-5 ml/s

2. MRI with Contrast for Hepatic Lesion Characterization

MRI abdomen with and without IV contrast is essential to better characterize the hepatic lesion 10:

• MRI has superior sensitivity for liver metastases compared to CT
• Can help distinguish benign lesions (hemangioma, cyst, focal nodular hyperplasia) from metastases
• Should include diffusion-weighted sequences

3. Endoscopic Ultrasound with Fine-Needle Aspiration (EUS-FNA)

EUS-FNA is the procedure of choice for tissue diagnosis [1, 1:

• Provides high-resolution imaging of the pancreatic mass
• Allows tissue sampling for cytologic/histologic confirmation
• Can assess vascular involvement
• Should be performed at an expert center given operator-dependency 7

4. Tumor Marker Testing

• CA19-9 should be measured [3, 9
• Elevated CA19-9 with these imaging findings significantly increases probability of malignancy (OR 7.5) 8
• Note: CA19-9 can be falsely elevated in biliary obstruction and is absent in Lewis antigen-negative patients (~10%)

5. Staging CT Chest

• Complete staging requires chest CT to evaluate for pulmonary metastases [10, 11

Prognosis

If Localized Disease (No Hepatic Metastasis)

The prognosis depends critically on resectability:

• If resectable (no vascular involvement, negative margins achievable):

  • Surgical resection offers only curative option [9, 10
  • 5-year survival for resected early-stage PDAC: approximately 20-30%
  • However, only 15-20% of patients have resectable disease at diagnosis [9, 10

• If borderline resectable or locally advanced:

  • Neoadjuvant chemotherapy ± radiation may be considered
  • Conversion to resectable status possible in select cases

If Metastatic Disease (Hepatic Lesion Confirmed as Metastasis)

The prognosis is poor:

• Median survival with modern chemotherapy (FOLFIRINOX or gemcitabine/nab-paclitaxel): 8-11 months 11
• 5-year survival for metastatic PDAC: <5%
• Treatment is palliative, focused on symptom control and quality of life
• Patients with good performance status (ECOG 0-1) should be offered systemic chemotherapy 11

Critical Prognostic Factors

The following will determine outcome [9, 10:

1. Presence or absence of metastatic disease (most important)
2. Vascular involvement (celiac axis, SMA, portal vein/SMV)
3. Tumor size and location
4. Performance status (ability to tolerate treatment)
5. CA19-9 level
6. Ability to achieve R0 resection (negative margins)

Common Pitfalls to Avoid

1. Delaying tissue diagnosis: Do not wait—proceed urgently to EUS-FNA. Early diagnosis is critical given rapid disease progression

2. Assuming the hepatic lesion is benign: In the context of pancreatic mass, liver lesions must be proven benign with MRI or biopsy

3. Inadequate imaging: Ensure proper pancreatic protocol CT was performed. Standard abdominal CT misses up to 30% of small pancreatic cancers 3

4. Missing the window for resection: Even brief delays can result in disease progression from resectable to unresectable

5. Not involving multidisciplinary team early: Patients should be discussed at multidisciplinary tumor board including surgical oncology, medical oncology, radiation oncology, and gastroenterology [9, 10

Summary of Likely Diagnosis and Prognosis

Most likely diagnosis: Pancreatic ductal adenocarcinoma of the pancreatic tail, potentially with hepatic metastasis (Stage IV) or at minimum locally advanced disease

Prognosis without hepatic metastasis: Guarded but potentially curable if resectable; 20-30% 5-year survival with complete resection

Prognosis with confirmed hepatic metastasis: Poor; median survival 8-11 months with chemotherapy, <5% 5-year survival

Immediate priority: Urgent EUS-FNA for tissue diagnosis, MRI liver for metastasis characterization, and multidisciplinary evaluation to determine resectability and treatment plan. Time is critical—every week of delay potentially impacts resectability and survival.